Pharmaceutical composition containing acetaminophen and ibuprofen
The solid oral dosage form prepared by jet grinding technology improves the dissolution rate and plasma concentration of ibuprofen, solves the problem of slow dissolution rate of existing ibuprofen oral dosage forms, and achieves a faster and lasting pain relief effect.
Patent Information
- Application Number
- CN202411208827.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2019-02-27
- Filing Date
- 2020-02-27
- Publication Date
- 2024-12-03
AI Technical Summary
The existing oral dosage forms of ibuprofen dissolve slowly in the body, resulting in slow increase in plasma concentrations, affecting the pain relief effect, and a higher re-administration rate.
The solid oral dosage form prepared by jet grinding technology reduces the particle size of ibuprofen and acetaminophen by adjusting the ratio of ibuprofen and adding surfactant, so that its dissolution rate in vitro is significantly accelerated and higher. plasma concentration.
The dissolution rate and plasma concentration of ibuprofen are significantly improved, achieving faster and lasting pain relief, reducing the need for pain recurrence.
Smart Images

Figure BDA0005019790690000081 
Figure BDA0005019790690000101 
Figure BDA0005019790690000111
Abstract
Description
Background Art
[0001] For various nonsteroidal anti-inflammatory drugs (NSAIDs), there is evidence that high, early plasma concentrations lead to better early pain relief, better overall pain relief, more sustained pain relief, and lower re-dosing rates. (Moore et al. (2015) British Journal of Clinical Pharmacology 80:381). For ibuprofen, more rapid absorption can lead to earlier and higher maximum plasma concentrations, which lead to earlier onset of analgesia and better overall analgesia and longer-lasting analgesia in a dental pain model. The effect of fast-acting formulations can be significant. In one study, 200 mg of a fast-acting formulation, ibuprofen salt, produced the same or better analgesia as 400 mg of ibuprofen acid and reduced the need for additional analgesics (Moore et al. (2014) Pain 155:14). The pharmacokinetics of ibuprofen can be altered by reducing the particle size to below 1000 nm (WO
[0002] 2010 / 121328). Summary of the invention
[0003] Solid oral unit dosage pharmaceutical compositions comprising acetaminophen (325 mg) and ibuprofen (97.5 mg) are described herein, having a higher maximum plasma concentration of ibuprofen compared to Maxigesic (325). Solid oral unit dosage pharmaceutical compositions comprising acetaminophen (500 mg) and ibuprofen (150 mg) are also described. These dosage forms are referred to as Fast Maxigesic 325 and Fast Maxigesic 500, respectively. The present disclosure features these pharmaceutical compositions and methods of producing and using these compositions.
[0004] Solid oral dosage forms described herein include ibuprofen (free acid), which dissolves particularly fast in vitro. The effect of increased in vitro dissolution rate on pharmacokinetic parameters is highly variable. In the case of this dosage form, the ibuprofen C maximum of the product produced by the rapidly dissolving ibuprofen increases significantly. Significantly, the ibuprofen particle size in this dosage form is greater than 1,000 nm.
[0005] Described herein are solid oral dosage forms comprising 325 mg acetaminophen and 97.5 mg ibuprofen or 500 mg acetaminophen and 150 mg ibuprofen, wherein the ibuprofen has a [D50] of 1-9 μm.
[0006] In various embodiments: the [D10] of ibuprofen is 1-3 μm; the [D90] of ibuprofen is 3-16 μm; the [D50] of ibuprofen is 2-8 μm, the [D10] is 1-3 μm and the [D90] is 4-16 μm; the dissolution rate of ibuprofen in the solid oral dosage form is such that when the solid oral dosage form is dissolved in 900 mL of 50 mM pH 5.0 at 37°C using USP Apparatus II (Paddle) with the speed set at 50 rpm. 5.8 When tested in phosphate buffer, 80% or more (e.g., at least 85% to 95% or 95% to 100%) of the ibuprofen dissolves in 15 minutes or less; the dosage form is a tablet (e.g., a coated tablet); the ratio of [D90] to [D50] is 4:1 to 1.5:1; the ratio of [D90] to [D50] is 3:1 to 1.5:1; the ratio of [D50] to [D10] is 4:1 to 1.5:1; the ratio of [D50] to [D10] is 3:1 to 1.5:1.
[0007] In some cases, the preparation process of the dosage form comprises jet milling a composition comprising 21-23% w / w ibuprofen and 73-75% w / w acetaminophen. In some cases, the jet milled composition further comprises a surfactant (such as sodium lauryl sulfate).
[0008] Also described is a method for treating pain (e.g., mild to moderate acute pain) comprising administering 1, 2, or 3 units of a solid oral dosage form comprising 325 mg acetaminophen and 97.5 mg ibuprofen. In some cases, administration is 1, 2, 3, or 4 times per day.
[0009] Also described is a method for treating pain (e.g., mild to moderate acute pain) comprising administering 1 or 2 units of a solid oral dosage form comprising 500 mg acetaminophen and 150 mg ibuprofen. In some cases, administration is 1, 2, 3, or 4 times per day.
[0010] Also described is a method for preparing a pharmaceutical composition comprising jet milling a composition comprising acetaminophen, ibuprofen, and a surfactant (e.g., sodium lauryl sulfate), wherein the ratio of acetaminophen to ibuprofen is 3:1 (w / w), under certain conditions and for a period of time, reducing the particle size of the ibuprofen to a median particle size (calculated as volume average) of 2-8 μm.
[0011] Also described is a method for preparing a pharmaceutical composition comprising jet milling a composition comprising acetaminophen, ibuprofen, and a surfactant (such as sodium lauryl sulfate), wherein the ratio of acetaminophen to ibuprofen is 3:1 (w / w), under certain conditions and for a period of time to achieve a median volume particle size of 4-15 μm.
[0012] In some cases: the [D90] of ibuprofen in Fast Maxigesic 325 and Fast Maxigesic 500 is greater than 2 μm (such as greater than 3, 4, 5 6, 7, 8, 9, 10, 11 or 12 μm) and less than one of the following: 18 μm, 17 μm 16 μm; 14 μm and 13 μm (preferably 3-17 μm). 3-16μm or 4-15μm); the [D50] of ibuprofen is greater than 1μm, 1.5μm, 2μm, 2.5μm, 3μm, 3.5μm, 4μm, 4.5μm, 5μm, 5.5μm, 6μm), but less than 12μm, 10μm, 9μm or 8μm (preferably 1-11μm, 1-10μm, 2-10μm, 2-9μm); the [D10] of ibuprofen is less than 7μm (for example 6.5, 6, 5.5, 5, 4.5, 4, 3.5, 3, 2.5, 2 or 1.5μm), but greater than 100nm; the ratio of [D90] to [D50] is 4:1 to 2:1; the ratio of [D50] to [D10] is 3:1 to 1.5:1 (all measurements are based on volume averages).
[0013] Also described herein is a method for treating pain (such as mild to moderate acute pain) comprising administering to a patient in need thereof a therapeutically effective dose (975 mg of acetaminophen + 292.5 mg of ibuprofen) of a rapid-acting Maxigesic 325 unit dosage form (325 mg of acetaminophen + 97.5 mg of ibuprofen / unit dose) up to 4 times a day (3900 mg of acetaminophen + 1170 mg of ibuprofen / day).
[0014] Also described herein is a method for treating pain (e.g., mild to moderate acute pain) comprising administering to a patient in need thereof a therapeutically effective dose (1,000 mg of acetaminophen + 300 mg of ibuprofen) of a rapid-acting Maxigesic 500 unit dosage form (500 mg of acetaminophen + 150 mg of ibuprofen per unit dose) up to 4 times per day (4,000 mg of acetaminophen + 1,200 mg of ibuprofen per day).
[0015] Additional dosage regimens for Rapid Maxigesic 325 include: 1 unit dose given 1, 2, 3, or 4 times per day; 2 unit doses given 1, 2, 3, or 4 times per day; 3 unit doses given 1, 2, 3, or 4 times per day. Additional dosage regimens for Rapid Maxigesic 500 include: 1 unit dose given 1, 2, 3, or 4 times per day and 2 unit doses given 1, 2, 3, or 4 times per day.
[0016] The dissolution rate of ibuprofen in a coated tablet containing 97.5 mg of ibuprofen is such that at least 75%, 80% or 85% of the ibuprofen is dissolved in 15 minutes or less (e.g., 14 minutes or less, 13 minutes or less, such as 85% can be dissolved in 15 minutes) when tested in 900 ml of pH 5.8 phosphate buffer (50 mM) using USP Apparatus II at 50 rpm and 37°C. For example, at least 85% can be dissolved in 12-19 minutes.
[0017] The dissolution rate of ibuprofen in a coated tablet containing 150 mg of ibuprofen is such that at least 75%, 80% or 85% of the ibuprofen is dissolved in 15 minutes or less (e.g., 14 minutes or less, 13 minutes or less, such as 85% can be dissolved in 15 minutes) when tested in 900 ml of pH 5.8 phosphate buffer (50 mM) using USP Apparatus II at 50 rpm and 37°C. For example, at least 85% can be dissolved in 12-19 minutes.
[0018] The dosage form may include various excipients. For example, the dosage form may include one or more of the following: a diluent, a lubricant, a disintegrant, a binder, and a wetting agent. For example, the dosage form may include one or more of the following: magnesium stearate, povidone, lactose, microcrystalline cellulose pregelatinized starch, hypromellose, sodium starch glycolate, sodium starch fumarate, sodium lauryl sulfate, and cross-linked sodium carboxymethyl cellulose. The tablet may be uncoated, or preferably, coated with a suitable coating agent.
[0019] The dry grinding apparatus used is preferably a jet mill (eg a spiral jet mill).
[0020] In another aspect, the present disclosure includes a method for manufacturing a pharmaceutical composition as described herein, comprising preparing a composition comprising ibuprofen and acetaminophen prepared by the method described herein or a composition as described herein together with a diluent, a lubricant, an excipient, a disintegrant, and a wetting agent into a pharmaceutically acceptable solid dosage form.
[0021] Content described herein may include one or more ranges of values (e.g., size, concentration, etc.). A range of values will be understood as all values within the range (including the values defining the range), as well as values adjacent to the range that result in the same or substantially the same result as the values immediately adjacent to the boundaries of the defined range.
[0022] In this specification and claims, unless the context requires otherwise, the word "comprise" or variations such as "include" or "contain" should be understood to mean including the stated integer or group of integers but not excluding any other integer or group of integers. It should also be noted that in this disclosure, especially in the claims and / or paragraphs, terms such as "comprise", "include", "contain", etc. may have the meaning given to it by U.S. patent law; for example, they may mean "include", "include", "contain", etc.
[0023] As used herein, "therapeutically effective amount" in relation to treatment methods, particularly drug dosage, refers to a dose that provides a specific pharmacological response, which dose is administered to a large number of subjects in need of such treatment. It is emphasized that a "therapeutically effective amount" administered to a specific subject in a specific situation is not always effective to treat the diseases described herein, even if the dose is considered a "therapeutically effective amount" by a person skilled in the art. It is further understood that drug dosage is measured as an oral dose in a specific situation, or with reference to the drug concentration measured in the blood.
[0024] Those skilled in the art will appreciate that it is easy to make changes and adjustments to the contents described herein beyond the specific description. It should be understood that the present invention includes all such changes and modifications. The present invention also includes all steps, features, compositions and materials mentioned or indicated in the specification, either individually or collectively, and any two or more or any and all combinations of the steps or features.
[0025] The present invention is not to be limited in scope to the specific embodiments described herein, which are intended for illustrative purposes only. Functionally equivalent products, compositions, and methods are expressly included within the scope of what is described herein.
[0026] Other aspects and advantages of the present disclosure will become apparent to those skilled in the art from reading the following description. DETAILED DESCRIPTION
[0027] Various rapid release, solid oral dosage forms containing 325 mg acetaminophen and 97.5 mg ibuprofen are described herein, which have higher maximum plasma concentrations of ibuprofen than the dosage form known as Maxigesic 325. Various rapid release, solid oral dosage forms containing 500 mg acetaminophen and 150 mg ibuprofen are also described below, which have higher plasma concentrations of ibuprofen than the dosage form known as Maxigesic 500.
[0028] Maxigesic 325 tablets contain acetaminophen (325 mg) and ibuprofen (97.5 mg), and Maxigesic 500 tablets contain acetaminophen (500 mg) and ibuprofen (150 mg). Both are given as a single dose, up to three tablets for the lower strength and two tablets for the higher strength. A single dose delivers similar amounts of acetaminophen in both cases, up to three tablets of Maxigesic 325: 975 mg acetaminophen and 292.5 mg ibuprofen, or two tablets of Maxigesic 500: 1000 mg acetaminophen and 300 mg ibuprofen.
[0029] Particle size
[0030] For measurements made using laser diffraction, the term "median particle size" is defined as the median particle size determined based on the volume of an equivalent spherical particle. Where the term median is used, it is understood to describe the particle size that divides the population in half, such that 50% of the population based on volume is either larger or smaller than that size. The median particle size is written as: [D 50 ] or D
[50] Or [D50], D50, D(0.50) or D[0.5] or similar forms. As used herein, [D 50 ] or D
[50] Or [D50], D50, D(0.50) or D[0.5] or similar forms should be considered as the average median particle size.
[0031] The term "Dx of a particle size distribution" refers to the xth percentile of the distribution based on the volume of an equivalent spherical particle; thus, D90 refers to the 90th percentile, D95 refers to the 95th percentile, and so on. Using D90 as an example, this is usually written as [D 90 ] or D
[90] Or [D90], D(0.90) or D[0.9] or similar. With respect to median particle size and Dx, uppercase D or lowercase d are interchangeable and have the same meaning.
[0032] The term "D(3,2)" refers to the area-weighted mean size or the Sauter diameter; the term "D(4,3)" refers to the volume-weighted mean size. A detailed description of how to calculate these values is known in the art and can be found, for example, in ISO 9276-2:2014(E).
[0033] For many materials using the methods of the present disclosure, the particle size can be easily measured. When the active material has poor water solubility and the matrix in which it is ground has good water solubility, the powder can be easily dispersed in an aqueous solvent. In this case, the matrix dissolves, leaving the active material dispersed in the solvent. The particle size in the suspension can then be measured by laser light diffraction.
[0034] drug
[0035] The medicaments of the present disclosure may include a pharmaceutically acceptable material, optionally together with a grinding matrix or at least a portion of a grinding matrix, in combination with one or more pharmaceutically acceptable carriers, and other agents commonly used to prepare pharmaceutically acceptable compositions.
[0036] As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible.
[0037] Pharmaceutically acceptable carriers according to the present disclosure may include one or more of the following examples:
[0038] (1) Surfactants and polymers, including but not limited to polyethylene glycol (PEG), polyvinyl pyrrolidone (PVP), sodium lauryl sulfate, polyvinyl alcohol, crospovidone, polyvinyl pyrrolidone-polyvinyl acetate copolymers, cellulose derivatives, hydroxypropyl methylcellulose, hydroxypropyl cellulose, carboxymethyl ethyl cellulose, hydroxypropyl methylcellulose phthalate, polyacrylates and polymethacrylates, urea, sugars, polyols and their polymers, emulsifiers, carbohydrate gums, starches, organic acids and their salts, vinyl pyrrolidone and vinyl acetate
[0039] (2) Binders, such as various celluloses and cross-linked polyvinyl pyrrolidone, microcrystalline cellulose, povidone, etc.; and or
[0040] (3) fillers, such as lactose monohydrate, anhydrous lactose, microcrystalline cellulose and various starches; and or
[0041] (4) Lubricants, such as colloidal silicon dioxide, talc, stearic acid, magnesium stearate, calcium stearate, sodium stearyl fumarate, etc.; and or
[0042] (5) sweeteners, such as any natural or artificial sweetener, including sucrose, xylitol, saccharin sodium, cyclamate, aspartame and acesulfame potassium; and or
[0043] (6) flavoring agents; and or
[0044] (7) preservatives such as potassium sorbate, methylparaben, propylparaben, benzoic acid and its salts, other parabens such as butylparaben, alcohols such as ethanol or benzyl alcohol, phenolic chemicals such as phenol, or quaternary compounds such as benzalkonium chloride; and or
[0045] (8) buffer; and or
[0046] (9) diluents, such as pharmaceutically acceptable inert fillers, for example, microcrystalline cellulose, lactose, calcium hydrogen phosphate, sugars and / or mixtures of any of the foregoing; and or
[0047] (10) Wetting agents such as docusate sodium, sodium lauryl sulfate, lecithin, poloxamer, polysorbate 80, sorbitan esters, tricaprylin, glyceryl monooleate, myristyl alcohol, and mixtures thereof; and or
[0048] (11) disintegrants; such as cross-linked sodium carboxymethyl cellulose, crospovidone, sodium starch glycolate, and or
[0049] (12) effervescent agents, for example effervescent couples, for example organic acids (e.g. citric acid, tartaric acid, malic acid, fumaric acid, adipic acid, succinic acid and alginic acid and anhydrides and acid salts), or carbonates (e.g. sodium carbonate, potassium carbonate, magnesium carbonate, sodium glycine carbonate, L-lysine carbonate and arginine carbonate) or bicarbonates (e.g. sodium bicarbonate or potassium bicarbonate); and or
[0050] (13) Other pharmaceutically acceptable excipients.
[0051] Example 1: Attritor Milling and Jet Milling to Improve Dissolution of Ibuprofen
[0052] Attritor milling of active pharmaceutical ingredients (APIs), whether dry or wet, is most often performed in the presence of a grinding matrix (i.e., one or more inactive ingredients that can aid in the particle size reduction of the API). For example, in a dry milling process, the API can be milled in the presence of lactose or another suitable excipient. Such milling can be used to reduce the median particle size to less than 1,000 nm. Due to the high drug loading required for this dosage form, acetaminophen was used as the grinding matrix for the attritor milling studies described below.
[0053] Ibuprofen, acetaminophen and sodium lauryl sulfate (SLS) were ground in an attritor using the conditions described in Table 1.
[0054] Table 1: Grinding conditions of attritor mill
[0055]
[0056] Attritor milling of a mixture of acetaminophen, ibuprofen and sodium lauryl sulfate (Table 1) was successful at a 200 g scale, with the median particle size of the ibuprofen being reduced to the submicron range (Table 2). In addition, the dissolution rate of the ibuprofen in the ground material, whether attritor milled or jet milled, was faster than that of the unground API (Table 3). However, the yield of attritor milling was relatively low due to agglomeration of the ground material.
[0057] As an alternative approach to potentially increase yield and scale up, co-jet milling was investigated. The formulations in Table 1 were processed in a 4" jet mill at 100 psig. As shown in Table 2, the ibuprofen size in the co-jet milled formulation (acetaminophen / ibuprofen / SLS) was larger than that produced by attritor milling.
[0058] Table 2: Particle size of ibuprofen
[0059] Dv10(μm) Dv50(μm) Dv90(μm) Ibuprofen (raw material) 24.2 51.3 94.5 Milling Intermediate 0.282 0.617 2.05 Co-jet milling intermediate 1.63 2.73 4.44
[0060] The ibuprofen dissolution rate of both milled formulations was greatly accelerated compared to the unmilled formulation, indicating that the reduction in particle size improved the dissolution rate of ibuprofen. However, although the ibuprofen particle size of the attritor milled material was much smaller than that of the co-jet milled material, the ibuprofen dissolution rates of the two milled materials (Table 3) were similar. This indicates that the co-jet milled material can overcome the dissolution rate-limiting solubility of ibuprofen despite the median particle size of ibuprofen being greater than 1,000 nm.
[0061] Table 3: Ibuprofen Dissolution Rates in Acetaminophen / Ibuprofen Powder Formulations
[0062]
[0063] method
[0064] Particle size
[0065] First, the sample was dispersed in 0.1HPC, 0.01N HCl, sonicated for 1 minute using a probe sonicator, and the particle size was measured. The sonicated sample was added to a laser diffraction wet sample cell, filled with 0.1% HPC in 0.01N HCl, stirred for 5 minutes, and then the sample was measured.
[0066] Dissolution rate
[0067] The solubility of the selected powder intermediate formulations was tested using USP Apparatus II, using 900 mL of 50 mM pH 5.8 media, 37°C, paddle speed 50 rpm. The powder was added to the top of the media filled container and the samples were analyzed by HPLC for results.
[0068] Example 2: Co-jet milling improves the solubility of ibuprofen
[0069] The results of jet milling indicate that a method can be provided for preparing dosage forms containing high drug loads of ibuprofen and acetaminophen. Jet milling was further investigated by manufacturing powder formulations using two different jet milling methods, both of which used the formulations in Table 4. In the first process, ibuprofen was jet milled alone and then blended with acetaminophen, SLS, and hydroxypropylcellulose. In the second process, all four ingredients were blended and then jet milled together.
[0070] Table 4: Formulations used to compare jet milling and co-jet milling
[0071]
[0072] The particle sizes of jet milled ibuprofen, whether jet milled alone or co-jet milled with acetaminophen, SLS and HPC, were similar, as shown in Table 5.
[0073] Table 5: Particle size of jet-milled and co-jet-milled ibuprofen
[0074]
[0075] It was unexpectedly discovered that when ibuprofen was co-jet milled with acetaminophen, SLS and hydroxypropylcellulose for size reduction, its dissolution rate was improved relative to ibuprofen that was jet milled for size reduction in the absence of acetaminophen, SLS and hydroxypropylcellulose, even though the two processes produced ibuprofen particles of similar size. Table 6 lists the dissolution rate data for 1) jet milled ibuprofen blended with acetaminophen, SLS and hydroxypropylcellulose after jet milling; and 2) ibuprofen co-jet milled with acetaminophen, SLS and hydroxypropylcellulose.
[0076] From the dissolution data in Table 6, it can be seen that the ibuprofen co-jet milled with acetaminophen, SLS and HPC completely dissolved within 2 minutes, while the ibuprofen milled without acetaminophen, SLS and HPC required 10 minutes to be more than 85% dissolved. Therefore, the presence of acetaminophen, SLS and HPC in the mill improved the dissolution rate of ibuprofen of similar size.
[0077] Table 6: Dissolution data for jet-milled and co-jet-milled ibuprofen
[0078]
[0079] The particle size and dissolution rate methods were the same as described in Example 1.
[0080] Example 3: Preparation of Fast Maxigesic 325 Tablets and Fast Maxigesic 500 Tablets
[0081] Acetaminophen (75.41% w / w), ibuprofen (22.62% w / w) and sodium lauryl sulfate (1.97% w / w) were blended together and the blend was milled using a spiral jet mill to achieve target volume particle sizes Dv50 <4.5 microns and Dv90 <14 microns. The milled blend ("drug intermediate" or DPI) was then blended with excipients and wet granulated using a high shear mixer and fluid bed dryer. The granules were screened / milled, blended with a lubricant and compressed into tablets. The tablets were then film coated. Table 7 shows the formulation of the milled intermediate and Tables 8 and 9 show the tablet formulations.
[0082] Table 7: Examples of fast-acting drug intermediates for Maxigesic 325 and 500
[0083] Element %w / w Acetaminophen, USP 75.41 Ibuprofen, USP 22.62 Sodium Lauryl Sulfate, USP 1.97 100.00
[0084] Table 8: Example of fast-acting Maxigesic (325) tablet formulation
[0085]
[0086] Table 9: Example of formulation of fast-acting Maxigesic (500) tablets
[0087]
[0088] Particle size
[0089] Several batches of DPI were analyzed to determine the particle size of ibuprofen in the co-jet milled intermediate. All tests were performed using laser light diffraction. To measure the particle size of ibuprofen, DPI was dispersed in an aqueous medium (0.1% HPC in 0.01N HCl) in which acetaminophen and SLS were soluble, leaving only the poorly soluble ibuprofen suspended for particle size testing. Specifically, the powder was added directly to the sample chamber and stirred for 5 minutes before the sample was measured. The results of this analysis are shown in Table 10.
[0090] Table 10: Particle size data of fast Maxigesic DPI
[0091]
[0092] Dissolution rate
[0093] The solubility of the selected tablet formulations was tested using USP Apparatus II, using 900 mL of 50 mM pH 5.8 media, 37°C, and a paddle speed of 50 rpm. One tablet was added to each medium-filled container and the samples were analyzed by HPLC to obtain the results.
[0094] Film coatings are present to aid swallowing, mask taste and enhance the aesthetics of the dosage form. Film coatings typically take several minutes to dissolve, creating some small lag time in dissolution. For comparison purposes, film coated tablets and uncoated tablet cores were studied. These batches of tablets were prepared using the DPIs in Table 11. The results of this analysis are described in Table 11.
[0095] Table 11. Rapid dissolution of Maxigesic 325
[0096]
[0097] In another study, the dissolution rate of ibuprofen in two different batches of fast Maxigesic 325 tablets (prepared as described above) was compared to the dissolution rate of Maxigesic 325 tablets (measured in pH 5.8 phosphate buffer as described above). The results are shown in Table 12. A similar comparison was made for fast Maxigesic 500 and Maxigesic 500 tablets. The results are shown in Table 13.
[0098] Table 12. Dissolution of Maxigesic 325 Rapid and Maxigesic 325 Tablets in pH 5.8 Phosphate Buffer
[0099]
[0100] Table 13: Dissolution of Maxigesic 500 and Fast Maxigesic 500 Tablets in pH 5.8 Phosphate Buffer
[0101]
[0102] From the above results it can be seen that it is possible to prepare solid oral dosage forms having greatly improved dissolution of ibuprofen despite the median particle size (average by volume) of ibuprofen being greater than 1 micron.
[0103] Example 4: Comparative Pharmacokinetic Analysis of Fast Maxigesic 325 and Maxigesic 325
[0104] Clinical studies were conducted to evaluate the Cmax of ibuprofen and the Cmax of acetaminophen in the fasting and fed states.
[0105] The data were compared using separate 90% CI, two-tailed, unpaired t-tests. Maxigesic Fast 325 and Maxigesic 325 were compared in the fed or fasted state. This allowed for significant differences to be detected at 10% or P ≤ 0.1. The study protocol had used 90% CIs to calculate mean differences in mean log-transformed data for acetaminophen and ibuprofen.
[0106] For acetaminophen in the fasting state, there were no statistically significant differences in Cmax between the formulations, Table 13.
[0107] Table 13: Acetaminophen Fasting C Maximal Values for Maxigesic 325 and Maxigesic 325 Fast
[0108] The difference between the means -459.1±1665 90% Confidence Interval -3243 to 2325 Percent difference between means -2.99%
[0109] For ibuprofen in the fasting state, there were statistically significant differences in Cmax between the formulations (Table 14)
[0110] Table 14: Ibuprofen Fasting C Max for Maxigesic 325 and Maxigesic 325 Fast
[0111] The difference between the means -2727±1443 90% Confidence Interval -5138 to -315.6 Percent difference between means 11.93%
[0112] This is an important advantage of this dosage form, as administration on an empty stomach is recommended to achieve rapid pain relief.
[0113] For acetaminophen in the fed state, there were no statistically significant differences in Cmax between formulations (Table 15).
[0114] Table 15: Acetaminophen Cmax for Maxigesic 325 and Maxigesic 325 Express
[0115] The difference between the means -813.1±996 90% Confidence Interval -2478 to 851.7 Percent difference between means 7.82%
[0116] Although a significant increase was again observed, there were no statistically significant differences in Cmax between formulations for ibuprofen in the fed state (Table 16).
[0117] Table 16: Ibuprofen Cmax for Maxigesic 325 and Maxigesic 325 Express
[0118] The difference between the means 2344±1362 90% Confidence Interval 67.02 to 4622 Percent difference between means 12.68%
[0119] In summary, the Cmax of ibuprofen was significantly higher in Maxigesic Fast (325) than in Maxigesic (325) in both the fed and fasted studies. The 90% confidence intervals did not overlap with 0, indicating a significant difference between the means. The difference between the ibuprofen means was greater than 11%, which is consistent with the Maxigesic Fast formulation providing a higher Cmax drug concentration of ibuprofen.
[0120] Example 5: Pharmacokinetic Analysis of Maxigesic 325.
[0121] The above formulations of Maxigesic 325 were subjected to pharmacokinetic analysis under fed and fasted conditions. The results of this study are shown in Tables 17-20.
[0122] Table 17: Ibuprofen PK values of Maxigesic Fast 325 in the fasting state
[0123] Pharmacokinetic parameters (N=30) <![CDATA[C 最大值 (ng / ml)]]> 25579.823±5996.24 <![CDATA[AUC 0→t (ng.h / ml)]]> 91888.7±24015.73 <![CDATA[AUC 0→∞ (ng.h / ml)]]> 95621.9±28252.68 <![CDATA[t 最大值 (h)*]]> 1.25(0.25-3.00) <![CDATA[K el (l / h)]]> 0.3076±0.06 <![CDATA[t 1 / 2el (h)]]> 2.35±0.57 <![CDATA[AUC 0→t / AUC 0→∞ 0 / 0]]> 96.82±3.22
[0124] Table 18: Ibuprofen PK Values of Maxigesic Fast 325 in the Fed State
[0125] Pharmacokinetic parameters (N=30) <![CDATA[C 最大值 (ng / ml)]]> 20834.673±5506.39 <![CDATA[AUC 0→t (ng.h / ml)]]> 71286.1±16546.13 <![CDATA[AUC 0→∞ (ng.h / ml)]]> 73449.6±17660.44 <![CDATA[t 最大值 (h)*]]> 1.25(0.75-6.00) <![CDATA[K el (l / h)]]> 0.3222±0.05 <![CDATA[t 1 / 2el (h)]]> 2.19±0.31 <![CDATA[AUC 0→t / AUC 0→∞ 0 / 0]]> 97.25±1.42
[0126] Table 19: Acetaminophen PK Values of Maxigesic Fast 325 in the Fasting State
[0127]
[0128] Table 20: Acetaminophen PK Values of Maxigesic Fast 325 in the Fed State
[0129] Pharmacokinetic parameters (N=30) <![CDATA[C 最大值 (ng / ml)]]> 11214.182±4084.46 <![CDATA[AUC 0→t (ng.h / ml)]]> 39826.6±11211.91 <![CDATA[AUC 0→∞ (ng.h / ml)]]> 42381.0±12086.45 <![CDATA[t 最大值 (h)*]]> 1.25(0.50-6.00) <![CDATA[K el (l / h)]]> 0.2303±0.03 <![CDATA[t 1 / 2el (h)]]> 3.05±0.37 <![CDATA[AUC 0→t / AUC 0→∞ 0 / 0]]> 94.16±2.30
[0130] Other Implementations
[0131] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
[0132] Although the present disclosure has been described in conjunction with specific embodiments, it will be understood that the disclosure may be further modified, and this application is intended to cover any variations, uses, or adaptations of the disclosure, generally in accordance with the principles of the disclosure, including departures from the disclosure within known or customary practices in the art to which the disclosure pertains, and may be applied to the essential features set forth above, within the scope of the claims.
[0133] Other implementations are within the scope of the following claims.
Claims
1. A solid oral dosage form comprising 325 mg acetaminophen and 97.5 mg ibuprofen or 500 mg acetaminophen and 150 mg ibuprofen, wherein the ibuprofen has a [D50] of 2-8 μm, a [D10] of 1-3 μm and a [D90] of 4-16 μm.
2. The solid oral dosage form of claim 1, wherein the dosage form is a tablet.
3. The solid oral dosage form of claim 1, wherein the ratio of [D90] to [D50] is 4:1 to 1.5:
1.
4. The solid oral dosage form of claim 1, wherein the ratio of [D90] to [D50] is 3:1 to 1.5:
1.
5. The solid oral dosage form of claim 1, wherein the ratio of [D50] to [D10] is 4:1 to 1.5:
1.
6. The solid oral dosage form of claim 1, wherein the ratio of [D50] to [D10] is 3:1 to 1.5:
1.
7. The solid oral dosage form of claim 1, wherein the ibuprofen has a [D50] of 4 μm, a [D10] of 2 μm, and a [D90] of 8 μm.
8. The solid oral dosage form of claim 1, wherein the ibuprofen has a [D50] of 3 μm, a [D10] of 2 μm, and a [D90] of 5 μm.
9. The solid oral dosage form of claim 1, wherein the ibuprofen has a [D50] of 3 μm, a [D10] of 2 μm, and a [D90] of 7 μm.
10. The solid oral dosage form of claim 1, wherein the ibuprofen has a [D50] of 5 μm, a [D10] of 3 μm, and a [D90] of 11 μm.
11. The solid oral dosage form of claim 1, wherein the ibuprofen has a [D50] of 5 μm, a [D10] of 2 μm, and a [D90] of 10 μm.
12. The solid oral dosage form of claim 1, wherein the ibuprofen has a [D50] of 7 μm, a [D10] of 3 μm, and a [D90] of 14 μm.
13. The solid oral dosage form of claim 1, wherein the ibuprofen has a [D50] of 7 μm, a [D10] of 3 μm, and a [D90] of 15 μm.
